Protagenic Therapeutics, Inc.new (PTIX) stock
PTIXOTCPharmaceutical PreparationsFiscal year ends March 31
Số liệu tài chính tới Q1 năm tài chính 2027, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 6, 2026
$0.75+0.00 (0.00%)
Close on Oct 19, 2026Market cap $1.36MP/E –Yield –
Protagenic Therapeutics, Inc.new r&d expenses
Research and development expenses are spending on new products and technology.
Protagenic Therapeutics, Inc.new's R&D Expenses for the twelve months ending Dec 31, 2024 was $3.84M, up 25.5% year over year. For fiscal 2024 it was $3.84M, up 25.5% from the year before. The highest annual figure on record is $3.84M in fiscal 2024.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $3.84M | +25.5% |
| FY2023 | Dec 31, 2023 | $3.06M | +92.8% |
| FY2022 | Dec 31, 2022 | $1.59M | +39.8% |
| FY2021 | Dec 31, 2021 | $1.14M | +62.4% |
| FY2020 | Dec 31, 2020 | $699.80K | -13.4% |
| FY2019 | Dec 31, 2019 | $807.95K | -8.3% |
| FY2018 | Dec 31, 2018 | $881.19K | +22.8% |
| FY2017 | Dec 31, 2017 | $717.45K | +71.7% |
| FY2016 | Dec 31, 2016 | $417.87K | +894.9% |
| FY2014 | Jun 30, 2014 | $42.00K | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q1 FY2027CQ1 2026 | Jun 30, 2026 | $109.93K | -92.5% |
| Q4 FY2024CQ4 2024 | Dec 31, 2024 | $134.58K | -86.7% |
| Q3 FY2024CQ3 2024 | Sep 30, 2024 | $16.96K | -98.5% |
| Q2 FY2024CQ2 2024 | Jun 30, 2024 | $19.14K | -97.1% |
| Q1 FY2024CQ1 2024 | Mar 31, 2024 | $1.46M | +319.7% |
| Q4 FY2023CQ4 2023 | Dec 31, 2023 | $1.01M | +292.9% |
| Q3 FY2023CQ3 2023 | Sep 30, 2023 | $1.12M | +124.2% |
| Q2 FY2023CQ2 2023 | Jun 30, 2023 | $671.17K | +318.1% |
| Q1 FY2023CQ1 2023 | Mar 31, 2023 | $348.03K | -48.0% |
| Q4 FY2022CQ4 2022 | Dec 31, 2022 | $257.52K | +75.7% |
| Q3 FY2022CQ3 2022 | Sep 30, 2022 | $501.37K | +94.9% |
| Q2 FY2022CQ2 2022 | Jun 30, 2022 | $160.52K | +14.2% |
| Q1 FY2022CQ1 2022 | Mar 31, 2022 | $669.84K | +13.1% |
| Q4 FY2021CQ4 2021 | Dec 31, 2021 | $146.57K | +248.5% |
| Q3 FY2021CQ3 2021 | Sep 30, 2021 | $257.28K | -52.3% |
| Q2 FY2021CQ2 2021 | Jun 30, 2021 | $140.59K | +170.3% |
| Q1 FY2021CQ1 2021 | Mar 31, 2021 | $592.35K | +798.1% |
| Q4 FY2020CQ4 2020 | Dec 31, 2020 | $42.06K | -91.9% |
| Q3 FY2020CQ3 2020 | Sep 30, 2020 | $539.77K | +1632.6% |
| Q2 FY2020CQ2 2020 | Jun 30, 2020 | $52.01K | -58.5% |
| Q1 FY2020CQ1 2020 | Mar 31, 2020 | $65.96K | -51.3% |
| Q4 FY2019CQ4 2019 | Dec 31, 2019 | $516.12K | +166.3% |
| Q3 FY2019CQ3 2019 | Sep 30, 2019 | $31.15K | -80.9% |
| Q2 FY2019CQ2 2019 | Jun 30, 2019 | $125.26K | -62.5% |
| Q1 FY2019CQ1 2019 | Mar 31, 2019 | $135.41K | -28.9% |
| Q4 FY2018CQ4 2018 | Dec 31, 2018 | $193.84K | -37.0% |
| Q3 FY2018CQ3 2018 | Sep 30, 2018 | $163.07K | +8.3% |
| Q2 FY2018CQ2 2018 | Jun 30, 2018 | $333.86K | +177.8% |
| Q1 FY2018CQ1 2018 | Mar 31, 2018 | $190.41K | +37.2% |
| Q4 FY2017CQ4 2017 | Dec 31, 2017 | $307.84K | +288.5% |
| Q3 FY2017CQ3 2017 | Sep 30, 2017 | $150.62K | +35.9% |
| Q2 FY2017CQ2 2017 | Jun 30, 2017 | $120.18K | -58.6% |
| Q1 FY2017CQ1 2017 | Mar 31, 2017 | $138.81K | +186.1% |
| Q4 FY2016CQ4 2016 | Dec 31, 2016 | $79.23K | +890.4% |
| Q3 FY2016CQ3 2016 | Sep 30, 2016 | $110.82K | +1008.2% |
| Q2 FY2016CQ2 2016 | Jun 30, 2016 | $290.58K | – |
| Q1 FY2016CQ1 2016 | Mar 31, 2016 | $48.52K | – |
| Q3 FY2014CQ1 2014 | Mar 31, 2014 | $8.00K | – |
| Q2 FY2014CQ4 2013 | Dec 31, 2013 | $10.00K | – |
See a number that looks wrong?